SCHEMBL6184470

SCHEMBL6184470

CNC(=O)c1cc(Br)cc(I)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49
TUBB8 Q3ZCM7 1/20 0.49
TUBA3E Q6PEY2 1/20 0.49
TUBA1A Q71U36 1/20 0.49
TUBA1C Q9BQE3 1/20 0.49
TUBB6 Q9BUF5 1/20 0.49
TUBB2B Q9BVA1 1/20 0.49
TUBB1 Q9H4B7 1/20 0.49
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC2 Q92769 1/20 0.44
LMNA P02545 1/20 0.42
CREBBP Q92793 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12476437 0.86 HDAC8 (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1006484 0.86 HDAC8 (0.52) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL15284299 0.86 HDAC8 (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL16049770 0.80 HDAC3 (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL25475684 0.79 SCN9A (0.41) ALDH1A1
SCHEMBL16396786 0.78 HDAC8 (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL200586 0.78 CA5A (0.43) LMNAHPGD
SCHEMBL29528630 0.77 NOTUM (0.57) LMNAHPGDTSHRALDH1A1
SCHEMBL232476 0.77 NOTUM (0.57) LMNAHPGDTSHRALDH1A1
SCHEMBL24150559 0.77 TUBB4A (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
CN-1468226-A Biphenyl derivatives and their use as ppar-gamma receptor activators �������о�����չ˽�����޹�˾ 2004-01-14 CN disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD TUBB4A 3992/4885TUBB 3953/4885TUBA3C 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.